Journal profile · UROLOGY & NEPHROLOGY
International Journal of Nephrology and Renovascular Disease
ISSN 1178-7058 · Dove Medical Press · United Kingdom
International Journal of Nephrology and Renovascular Disease: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.7 (journal website); JCR Q2 (journal website); fully open access; APC about USD 3,565; median 101 days to acceptance (71 articles, last 24 months); acceptance rate 26% (journal website); 33 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
International Journal of Nephrology and Renovascular Disease is published by Dove Medical Press and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Dialysis and Renal Disease Management, Chronic Kidney Disease and Diabetes and Renal Diseases and Glomerulopathies, together about 40.9% of its articles. Its main subfields are Nephrology. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Dr Yin Wang International Journal of Nephrology and Renovascular Disease is an international, peer-reviewed, open-access journal focusing on the pathophysiology of the kidney and vascular supply. Epidemiology, screening, diagnosis, and treatment interventions are covered as well as basic science, biochemical and immunological studies. The International Journal of Nephrology and Renovascular Disease will no longer consider meta-analyses for publication. In particular, emphasis will be given to: Chronic kidney disease Complications of renovascular disease Imaging techniques Renal hypertension Renal cancer Treatment including pharmacological and transplantation Dialysis and treatment of complications of dialysis and renal disease Quality of Life Patient satisfaction and preference Health economic evaluations The journal welcomes submitted papers covering original research, basic science, clinical studies, reviews & evaluations, guidelines, expert opinion and commentary, case reports and extended reports. The main focus of the journal will be to publish research and clinical results in humans, but preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies and interventions. Updated 1 August 2025
From the journal's Aims & Scope
Research area (LetPub): UROLOGY & NEPHROLOGY
Editor-in-chief Wang IndependentPublisher website
Editorial board by country: 2 in mainland China (about 5%); most named United States 17, Italy 10, Mainland China 2, Canada 2, Türkiye 2 (38 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Dialysis and Renal Disease ManagementMedicine19.4%
- Chronic Kidney Disease and DiabetesMedicine13.4%
- Renal Diseases and GlomerulopathiesMedicine8.1%
- Acute Kidney Injury ResearchMedicine7.7%
- Parathyroid Disorders and TreatmentsMedicine6.2%
- Blood Pressure and Hypertension StudiesMedicine4%
- Central Venous Catheters and HemodialysisHealth Professions3.5%
- Renal and Vascular PathologiesMedicine3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Urology & Nephrology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Urology & Nephrology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
SJR, CiteScore, Impact FactorPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.7Publisher website ·
- 5-year impact factor (publisher)
- 3.9Publisher website ·
- CiteScore 2026-06
- 3.9LetPub ·
- CiteScore (publisher) 2025
- 0.9Publisher website ·
- SJR 2026-06
- 0.6LetPub ·
- SNIP 2026-06
- 0.9LetPub ·
- h-index
- 53OpenAlex ·
- i10-index
- 269OpenAlex ·
- 2-year mean citedness
- 2.11OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 32LetPub ·
- Downloads per year (publisher)
- 91,437Publisher website ·
Articles by year OpenAlex count · 557 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 30 | 30 | 2 |
| 2025 | 33 | 33 | 59 |
| 2024 | 33 | 33 | 142 |
| 2023 | 26 | 26 | 262 |
| 2022 | 33 | 33 | 401 |
| 2021 | 47 | 47 | 665 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
101 daysMedian, submission to acceptance · P25–P75 71 days – 122 days
- Acceptance to online
- median 13 days (71 articles)
- Submission to online
- median 116 days
- Sample
- 71 articles with submission and acceptance dates (76 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 26%Publisher website ·
- Desk decision
- 40 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,565 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — | |
| LetPub | USD 2,990 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted3
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- original researchOriginal ResearchLength not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics
- Publication ethics
COPE member Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1178-7058
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about International Journal of Nephrology and Renovascular Disease
What CAS zone is International Journal of Nephrology and Renovascular Disease in?
In the 2025 upgraded edition of the CAS Journal Ranking, International Journal of Nephrology and Renovascular Disease is in Zone 4 of Medicine, and in Zone 4 of the minor category Urology & Nephrology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of International Journal of Nephrology and Renovascular Disease?
The journal's website gives an impact factor of 2.7 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 3.9, h-index 53.
How long does peer review take at International Journal of Nephrology and Renovascular Disease?
Based on the dates recorded on 71 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 101 days (interquartile range 71–122 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 26%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is International Journal of Nephrology and Renovascular Disease in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Where are the editorial board members of International Journal of Nephrology and Renovascular Disease based?
Of the 38 board members whose country the journal's board page names, 2 (about 5%) are in mainland China; the countries named most often are United States (17), Italy (10) and Mainland China (2). Counted from the institutions listed on the board page; for reference only.
Which databases index International Journal of Nephrology and Renovascular Disease?
According to LetPub and DOAJ records, International Journal of Nephrology and Renovascular Disease is indexed in ESCI, Scopus and DOAJ.
Is International Journal of Nephrology and Renovascular Disease open access, and what is the APC?
International Journal of Nephrology and Renovascular Disease is a fully open-access journal. APC about USD 3,565.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .